Nuclear medicine and biology

publication venue for

Pretargeted alpha therapy in MUC16-positive high-grade serous ovarian cancer.. 140-141. 2024
[⁸⁹Zr]ZrCl₄ for direct radiolabeling of DOTA-based precursors.. 136-137. 2024
Transcatheter pseudo-vascular isolation for localization and concentration of a large molecule theranostic probe into a transgenic OncoPIG kidney tumor.. 136-137. 2024
Visualization of a novel human monoclonal antibody against Claudin-3 for targeting ovarian cancer.. 114-115. 2022
Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation.. 86-87. 2020
Design and preclinical evaluation of nanostars for the passive pretargeting of tumor tissue.. 84-85. 2020
Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[¹⁸F]fluoro-d-glucose positron emission tomography in oral cancer imaging.. 84-85. 2020
Multimodality labeling strategies for the investigation of nanocrystalline cellulose biodistribution in a mouse model of breast cancer.. 80-81. 2019
A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals.. 71. 2019
[¹⁸F]RPS-544: A PET tracer for imaging the chemokine receptor CXCR4.. 60. 2018
Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of ⁶⁸Ga³⁺, ¹¹¹In³⁺, ¹⁷⁷Lu³⁺ and ²²⁵Ac³.. 55. 2017
Continuation of comprehensive quality control of the itG ⁶⁸Ge/⁶⁸Ga generator and production of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-PSMA-HBED-CC for clinical research studies.. 53. 2017
Copper-64 labeled liposomes for imaging bone marrow.. 43. 2016
A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.. 43. 2016
Synthesis and evaluation of an (18)F-labeled pyrimidine-pyridine amine for targeting CXCR4 receptors in gliomas.. 43. 2016
Synthesis of [11C]palmitic acid for PET imaging using a single molecular sieve 13X cartridge for reagent trapping, radiolabeling and selective purification.. 42. 2015
Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution.. 42. 2014
PET quantification with a histogram derived total activity metric: superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients.. 41. 2014
Influence of free fatty acids on glucose uptake in prostate cancer cells.. 41. 2013
Antilipolytic drug boosts glucose metabolism in prostate cancer.. 40. 2013
An improved strategy for the synthesis of [¹⁸F]-labeled arabinofuranosyl nucleosides.. 39. 2012
The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.. 38. 2011
Improved synthesis of 2'-deoxy-2'-[18F]-fluoro-1-beta-D-arabinofuranosyl-5-iodouracil ([18F]-FIAU).. 37. 2010
In vivo characterization of a reporter gene system for imaging hypoxia-induced gene expression.. 36. 2009
Standardized methods for the production of high specific-activity zirconium-89.. 36. 2009
Radiosynthesis of [(131)I]IAZGP via nucleophilic substitution and its biological evaluation as a hypoxia marker - is specific activity a factor influencing hypoxia-mapping ability of a hypoxia marker?. 36. 2009
(64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity.. 36. 2009
Melanoma imaging using (111)In-, (86)Y- and (68)Ga-labeled CHX-A''-Re(Arg11)CCMSH.. 36. 2009
Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.. 35. 2008
Syntheses and biological activities of novel 2-methoxyestradiol analogs, 2-fluoroethoxyestradiol and 2-fluoropropanoxyestradiol, and a radiosynthesis of 2-[(18)F]fluoroethoxyestradiol for positron emission tomography.. 35. 2008
Evaluation of a bromine-76-labeled progestin 16alpha,17alpha-dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studies.. 35. 2008
Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the "glucose-corrected" SUV.. 35. 2008
Chemosorption of radiometals of interest to nuclear medicine by synthetic melanins.. 35. 2008
Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines.. 35. 2008
Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.. 35. 2008
Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma.. 34. 2007
Radiolabeled high affinity peptidomimetic antagonist selectively targets alpha(v)beta(3) receptor-positive tumor in mice.. 34. 2007
Three-dimensional maximum a posteriori (MAP) imaging with radiopharmaceuticals labeled with three Cu radionuclides.. 33. 2006
Animal-specific positioning molds for registration of repeat imaging studies: comparative microPET imaging of F18-labeled fluoro-deoxyglucose and fluoro-misonidazole in rodent tumors.. 33. 2006
Imaging herpes viral thymidine kinase-1 reporter gene expression with a new 18F-labeled probe: 2'-fluoro-2'-deoxy-5-[18F]fluoroethyl-1-beta-d-arabinofuranosyl uracil.. 32. 2005
Preparation of high specific activity (86)Y using a small biomedical cyclotron.. 32. 2005
Breast imaging: a surgeon's prospective.. 32. 2005
Measurement of input functions in rodents: challenges and solutions.. 32. 2005
Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM.. 32. 2005
Methoxyphenylethynyl, methoxypyridylethynyl and phenylethynyl derivatives of pyridine: synthesis, radiolabeling and evaluation of new PET ligands for metabotropic glutamate subtype 5 receptors.. 32. 2005
Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors.. 32. 2005
Investigation into 64Cu-labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents.. 32. 2005
Basic characterization of 64Cu-ATSM as a radiotherapy agent.. 32. 2005
Semi-automated 86Y purification using a three-column system.. 31. 2004
Radiosynthesis of [18F] N-(3-Fluoropropyl)-2-beta-Carbomethoxy-3-beta-(4-Bromophenyl) Nortropane and the regional brain uptake in non human primate using PET.. 31. 2004
Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals.. 30. 2003
Synthesis of dendrimer-based biotin radiopharmaceuticals to enhance whole-body clearance.. 30. 2003
Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG.. 30. 2003
Lowering of pI by acylation improves the renal uptake of 99mTc-labeled anti-Tac dsFv: effect of different acylating reagents.. 29. 2002
PET examination of [(11)C]5-methyl-6-nitroquipazine, a radioligand for visualization of the serotonin transporter.. 29. 2002
Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors.. 29. 2002
Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications.. 29. 2002
Synthesis and characterization of (99m)Tc- and (188)Re-complexes with a diamido-dihydroxymethylenephosphine-based bifunctional chelating agent (N(2)P(2)-BFCA).. 29. 2002
Synthesis and evaluation of a macrocyclic bifunctional chelating agent for use with bismuth radionuclides.. 28. 2001
High yield direct 76Br-bromination of monoclonal antibodies using chloramine-T.. 26. 1999
99mTc-monoclonal antibody radiolabeled via hydrazino nicotinamide derivative for imaging disialoganglioside G(D2)-positive tumors.. 26. 1999
High purity production and potential applications of copper-60 and copper-61.. 26. 1999
In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake.. 26. 1999
Evaluation of 99mTc-mercaptoacetyltriglycine-biocytin as a new hepatobiliary imaging agent in mice coinjected with bilirubin.. 26. 1999
Measurement of P-glycoprotein expression in human neuroblastoma xenografts using in vitro quantitative autoradiography.. 26. 1999
Use of 99mTc-mercaptoacetyltriglycine (MAG3)-biocytin hepatobiliary scintigraphy to study the protective effect of a synthetic enzyme inhibitor on acute hepatotoxicity in mice.. 25. 1998
Similarities in the biodistribution of iodine-labeled anti-Tac single-chain disulfide-stabilized Fv fragment and anti-Tac disulfide-stabilized Fv fragment.. 25. 1998
Biodistribution of [64Cu]Cu2+ and variance of metallothionein during tumor treatment by copper.. 25. 1998
In vitro and in vivo evaluation of structure-stability relationship of 111In- and 67Ga-labeled antibody via 1B4M or C-NOTA chelates.. 24. 1997
Radiosynthesis of [18F] N-3-fluoropropyl-2-beta-carbomethoxy-3-beta-(4-iodophenyl) nortropane and the first human study with positron emission tomography.. 23. 1996
Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses.. 23. 1996
In vivo imaging and specific targeting of P-glycoprotein expression in multidrug resistant nude mice xenografts with [125I]MRK-16 monoclonal antibody.. 22. 1995
A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies.. 22. 1995
Effective targeting of magnetic radioactive 90Y-microspheres to tumor cells by an externally applied magnetic field. Preliminary in vitro and in vivo results.. 22. 1995
Calculated and TLD-based absorbed dose estimates for I-131-labeled 3F8 monoclonal antibody in a human neuroblastoma xenograft nude mouse model.. 22. 1995
Application of high affinity binding concept to radiolabel avidin with Tc-99m labeled biotin and the effect of pI on biodistribution.. 21. 1994
Current status of radioimmunodetection.. 21. 1994
Current status of radioimmunotherapy.. 21. 1994
Gallium-67-citrate imaging in nuclear oncology.. 21. 1994
Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen.. 21. 1994
Evaluation of a new DTPA-derivative chelator: comparative biodistribution and imaging studies of 111In-labeled B3 monoclonal antibody in athymic mice bearing human epidermoid carcinoma xenografts.. 20. 1993
G2M arrest and apoptosis in murine T lymphoma cells following exposure to 212Bi alpha particle irradiation.. 20. 1993
Human reporter genes: potential use in clinical studies. 2007
Reporter gene imaging: potential impact on therapy. 2005
PET imaging with ⁸⁹Zr: from radiochemistry to the clinic. 2012
Copper radionuclides and radiopharmaceuticals in nuclear medicine. 1996

VIVO Weill Cornell Medical College

Nuclear medicine and biology Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)